Advertisement
Saturday, Oct 08, 2022
Outlook.com
Outlook.com

Drug-Eluting Cardiac Stent Becomes Further Cheaper After Price Revision

Drug-Eluting Cardiac Stent Becomes Further Cheaper After Price Revision
| File-Representative Image
Drug-Eluting Cardiac Stent Becomes Further Cheaper After Price Revision
outlookindia.com
2018-02-12T21:26:47+05:30

The National Pharmaceutical Pricing Authority (NPPA) today revised the price of coronary stents after a year of price control.

The prices of drug eluting stents, which are the most commonly used during coronary angioplasty, has been revised downwards to Rs 27,890 from Rs 30,180. The price of bare metal stents has gone by slightly to Rs 7,660 from Rs 7,400, capping the trade margins at 8%.

The move came after several negotiations and deliberations by the NPPA with concerned stakeholders and civil society.  The pricing authority refused to give in to demand by several multinational stent manufacturing companies for sub-categorisation of drug eluting stents.

READ ALSO: No Heart In This Mart

The order on the pricing of the stents released by the NPPA on 12th February 2018 reads, “The issue of further sub classification of drug eluting stents was referred to the ministry of health and family welfare for ascertaining the expert views of the NLEM core committee of cardiac stents… which after giving opportunity to concerned stakeholders with due consideration has decided that there is no case for sub classification of DES in light of lack of enough clinical evidence to support superiority of one DES or other.”

READ ALSO: Cheaper Stents Make No Hearty Dent

Civil society has welcomed the move and hailed it as a decisive step in favour of ensuring affordability to patients. “We are glad that the Government did not cave to massive pressure that was being exerted by the industry for differential pricing without any scientific basis,” states a statement released by the all India drug action network.

READ ALSO: Heart For Mart Sake

Additionally, referring to the NPPA’s release of data on the trade margins involved in catheters, balloons, and guidewires, the statement says, “Expansion of price control to these devices is a necessary step to making procedures like angioplasty/angiogram more affordable and accessible to patients.”

READ ALSO: Doctors And Their Devices

Manufacturers though are unhappy with the move. A statement released by Pavan Chaudhary, managing director of the medical technologies association of India, said the move was disappointing. “It will limit patient choice and the availability of innovative technologies in the market. The only saving grace in the order is NPPA's expression that it is open to receiving stakeholder views. Taking that in earnest, we will stay engaged, he says.

The order is implementable from 13 February 2018 and is valid for a year.

Advertisement

Outlook Newsletters

Advertisement
Advertisement
Advertisement

Read More from Outlook

Lament Of Separation: Songs Of Habba Khatun, Last Queen Of Kashmir, Still Echo In Valley

Lament Of Separation: Songs Of Habba Khatun, Last Queen Of Kashmir, Still Echo In Valley

In happy times and sad, Habba Khatun’s sensuous songs make both young and old emotional. With the never-ending conflict bringing tragedies to every doorstep, Habba’s lyrics of separation amplify their mourning.

How Indian Laws Govern People’s Right To Love And Live

How Indian Laws Govern People’s Right To Love And Live

In India, only those relationships between a man and a woman are considered to be legitimate when there is a marriage between the two.

Kohli Quits Test Captaincy, Leaves Leadership Vacuum

Kohli Quits Test Captaincy, Leaves Leadership Vacuum

Virat Kohli, 33, had recently stepped down as India's T20I captain and was subsequently removed as the ODI captain.

UP Elections 2022: How Congress Is Harnessing Power Of 'Persecuted' Women To Counter BJP

UP Elections 2022: How Congress Is Harnessing Power Of 'Persecuted' Women To Counter BJP

A Mahila Congress leader, who is the face of the ‘Ladki Hoon, Lad Sakti Hoon’ campaign, however, has accused the party of anti-women bias after she was denied a ticket.

Advertisement